Journal Scope
Inventi Rapid/Impact: Pharmacokinetics & Pharmacodynamics is the peer reviewed journal of Pharmaceutical Sciences. This journal is having the research and review paper related to the study of drug absorption, distribution, metabolism and excretion including all application of pharmacokinetics principles for the effective management of drugs. The journal helps in understanding of drug action, therapy, design, development, and kinetics of drug disposition and drug action, clinical pharmacokinetics, factors affecting formation and disposition of drug metabolites, dosage form evaluation from animals and humans, bioavailabilty studies, scaling from animals to humans, and in vitro and in vivo correlations, computational and statistical methods used for the modeling, analysis, interpretation, and simulation of pharmacokinetic and pharmacodynamic data.
|
PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF NEWLY DEVELOPED DEXIBUPROFEN SUSTAINED RELEASE FORMULATIONS
|
|
|
Selvadurai Muralidharan
|
|
Pharmacokinetic-pharmacodynamic (PK-PD) modeling has emerged as a major tool in clinical pharmacology to optimize drug
use by designing rational dosage forms and dosage regimes. Quantitative representation of the dose-concentration-response
relationship should provide information for the prediction of the level of response to a certain level of drug dose. This paper
describes the experimental details of the preformulation study, tablet manufacture, optimization, and bioanalytical methods for
the estimation of dexibuprofen in human plasma. The hydrophilic matrix was prepared with xanthen gum with additives Avicel
PH 102. The effect of the concentration of the polymer and different filler, on the in vitro drug release, was studied. Various
pharmacokinetic parameters including AUC0–t, AUC0–8, Cmax, Tmax, T1/2, and elimination rate constant (Kel) were determined
from the plasma concentration of both formulations of test (dexibuprofen 300 mg) and reference (dexibuprofen 300 mg tablets).
The merits of PK-PD in the development of dosage forms and how PK-PD model development necessitates the development of
new drugs and bio analytical method development and validation are discussed. The objectives of the present study, namely, to
develop and validate the methods to estimate the selected drugs in the biological fluids by HPLC, the development of in vitro
dissolution methods, and PK-PD model development have been described....
More
|
|
|
EFFECTS OF BERBERINE AND HWANGRYUNHAEDOK-TANG ON ORAL BIOAVAILABILITY AND PHARMACOKINETICS OF CIPROFLOXACIN IN RATS
|
|
|
Youn-Hwan Hwang, Won-Kyung Cho, Doorye Jang, Jeong-Ho Ha, Kiyoun Jung, Hyo-In Yun, Jin Yeul Ma
|
|
Hwangryunhaedok-Tang (HR) and berberine-containing single herbs are used to treat bacterial infection and inflammatory
diseases in eastern Asia. The combination of berberine-containing herbal medicines and ciprofloxacin can be an excellent
antibacterial chemotherapy against multidrug resistance bacteria. To evaluate the pretreatment effect of berberine and HR,
vehicle, berberine (25 and 50 mg/kg/day), and HR (1.4 g/kg/day) were daily administered to rats for five consecutive days. On
day 6, ciprofloxacin was administered (10 mg/kg, i.v. and 20 mg/kg, p.o.) to rats. To assess cotreatment effect of berberine and
ciprofloxacin, berberine (50 mg/kg) and ciprofloxacin (20 mg/kg) were coadministered by single oral gavage. Pharmacokinetic data
were estimated by noncompartmental model. Compared with ciprofloxacin alone (control group), coadministration of berberine
(50 mg/kg) and ciprofloxacin significantly decreased Cmax of ciprofloxacin (P < 0.05). In addition, the pretreatment of berberine
(50 mg/kg/day) and HR (1.4 g/kg/day) significantly decreased Cmax and AUC0?8, compared with control group (P < 0.05). The
oral bioavailability of ciprofloxacin was reduced by cotreatment of berberine and pretreatment of berberine and HR. Our results
suggest that the expression of P-glycoprotein and organic anion and/or organic cation transporters (OAT/OCT) could take a role
in reduced oral bioavailability of ciprofloxacin by berberine and HR....
More
|
|
|
THE PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF AZITHROMYCIN FOR LIPOPOLYSACCHARIDE-INDUCED DEPRESSIVE-LIKE BEHAVIOR IN MICE
|
|
|
Kun Hao, Qu Qi, Haiping Hao, Guangji Wang, Yuancheng Chen, Yan Liang, Lin Xie
|
|
A mechanism-based model was developed to describe the time course of lipopolysaccharide-induced depressive-like
behavior and azithromycin pharmacodynamics in mice. The lipopolysaccharide-induced disease progression was monitored
by lipopolysaccharide, proinflammatory cytokines, and kynrenine concentration in plasma. The depressive-like behavior was
investigated by forced swimming test and tail suspension test. Azithromycin was selected to inhibit the surge of
proinflammatory cytokines induced by lipopolysaccharide. Disease progression model and azithromycin pharmacodynamics
were constructed from transduction and indirect response models. A delay in the onset of increased
proinflammatory cytokines, kynrenine, and behavior test compared to lipopolysaccharide was successfully characterized
by series transduction models. The inhibition of azithromycin on proinflammatory cytokines was described by an indirect
response model. After lipopolysaccharide challenging, the proinflammatory cytokines, kynrenine and behavior tests would
peak approximately at 3, 12, and 24 h respectively, and then the time courses slowly declined toward a baseline state after
peak response. During azithromycin administration, the peak levels of proinflammatory cytokines, kynrenine and behavior
indexes decreased. Model parameters indicated that azithromycin significantly inhibited the proinflammatory cytokines
level in plasma and improved the depressive-like behavior induced by inflammation. The integrated model for disease
progression and drug intervention captures turnovers of proinflammatory cytokines, kynrenine and the behavior results in
the different time phases and conditions...
More
|
|
|
|
E- ISSN: 2250-0251
P- ISSN: 2249-3549
Inventi Impact Pharmacokinetics & Pharmacodynamics
|
|
Frequency: Quarterly
E- ISSN: 2250-0251
P- ISSN: 2249-3549
Index Copernicus: 4.30
Abstracted/ Indexed in: Index Copernicus, Ulrich’s International Periodical Directory & Google Scholar, SCIRUS, Journal Seek (Genamics), PSOAR, getCITED
|
|